A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

被引：0
|
作者：
Andrew H. Ko
Alan P. Venook
Emily K. Bergsland
R. Kate Kelley
W. Michael Korn
Elizabeth Dito
Brian Schillinger
Janet Scott
Jimmy Hwang
Margaret A. Tempero
机构：
[1] University of California at San Francisco Helen Diller Family Comprehensive Cancer Center,
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词：
Bevacizumab; Circulating endothelial cells; Erlotinib; Pancreatic cancer; Phase II; Refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1051 / 1057
页数：6
相关论文
共 50 条
  • [1] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [2] Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Kulke, Matthew H.
    Blaszkowsky, Lawrence S.
    Ryan, David P.
    Clark, Jeffrey W.
    Meyerhardt, Jeffrey A.
    Zhu, Andrew X.
    Enzinger, Peter C.
    Kwak, Eunice L.
    Muzikansky, Alona
    Lawrence, Colleen
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4787 - 4792
  • [3] A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC)
    Ko, A. H.
    Dito, E.
    Schillinger, B.
    Venook, A. P.
    Bergsland, E. K.
    Korn, W. M.
    Tempero, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Morizane, Chigusa
    Okusaka, Takuji
    Furuse, Junji
    Ishii, Hiroshi
    Ueno, Hideki
    Ikeda, Masafumi
    Nakachi, Kohei
    Najima, Mina
    Ogura, Takashi
    Suzuki, Eiichiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 313 - 319
  • [5] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Takuji Okusaka
    Junji Furuse
    Hiroshi Ishii
    Hideki Ueno
    Masafumi Ikeda
    Kohei Nakachi
    Mina Najima
    Takashi Ogura
    Eiichiro Suzuki
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 313 - 319
  • [6] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane, C.
    Okusaka, T.
    Furuse, J.
    Ishii, H.
    Ueno, H.
    Ikeda, M.
    Najima, M.
    Hirokawa, S.
    Nakachi, K.
    Ogura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
  • [7] A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
    Renouf, D. J.
    Tang, P. A.
    Hedley, D.
    Chen, E.
    Kamel-Reid, S.
    Tsao, M. S.
    Tran-Thanh, D.
    Gill, S.
    Dhani, N.
    Au, H. J.
    Wang, L.
    Moore, M. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (11) : 1909 - 1915
  • [8] PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER
    Javle, M.
    Reddy, S.
    Varadhachary, G.
    Kaseb, A.
    Fogelman, D.
    Wolff, R.
    Abbruzzese, J.
    PANCREAS, 2008, 37 (04) : 476 - 476
  • [9] Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer
    Javle, M.
    Fogelman, D.
    Kaseb, A.
    Varadhachary, G.
    Wolff, R.
    Abbruzzese, J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 104 - 104
  • [10] Gemcitabine and oxaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer: A phase II study.
    Van Laethem, JL
    Polus, M
    Marechal, R
    Demols, A
    Gay, F
    Marijken, M
    Hendlisz, A
    Peeters, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 343S - 343S
12345